Skip to main content
SpringerLink
Log in

Sekundäre Pflanzenstoffe

Secondary plant products

  • In der Diskussion: Komplementäre Onkologie
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Sekundäre Pflanzenstoffe haben gemäß präklinischen und epidemiologischen Daten interessante Eigenschaften bei der Prävention in der Onkologie. Während die Bedeutung einer gesunden Ernährung unbestritten ist, sind jedoch die epidemiologischen Daten für einzelne dieser Stoffe noch widersprüchlich. Prävention kann nicht auf einen einzelnen Pflanzenstoff oder eine Gruppe von einzelnen sekundären Pflanzenstoffen aufgebaut werden. Präklinisch liegen für alle diese Substanzen ebenfalls interessante Daten bezüglich ihrer direkten antitumoralen Wirkung vor. Sie weisen gleichzeitig aber auch auf das hohe Interaktionspotenzial hin und zeigen auch, dass die hochdosierte Einnahme von wirkungsvollen sekundären Pflanzenstoffen potenziell schädigende Wirkungen hat. Der Einsatz in Form von Nahrungsergänzungsmitteln außerhalb von klinischen Studien ist nicht empfehlenswert.

Abstract

Epidemiological data show that antitumoral plant foods are relevant for the prevention of cancer. Although nobody will deny the usefulness of a healthy diet, epidemiological data for single substances are contradictory. Prevention cannot be realized with the consumption of one or a defined mixture of some of these substances. Interesting data from preclinical experiments show that some of the identified molecules also have potential as antitumoral agents. These data also reveal a potential for interactions and, in some studies, even a possible direct negative influence in clinical use. Further controlled clinical studies are therefore mandatory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Sun CL et al (2006) Green tea, black tea and colorectal cancer risk. Carcinogenesis 27(7):1301–1309

    Article  PubMed  CAS  Google Scholar 

  2. Myung SK et al (2008) Green tea consumption and risk of stomach cancer: A meta-analysis of epidemiologic studies. Int J Cancer

  3. Seely D et al (2005) The Effect of Green tea consumption on Incidence of breast cancer and recurrence of breast cancer, a systematic Review and Meta-analysis. Integr Cancer Ther 4(2):144–155

    Article  PubMed  Google Scholar 

  4. Kurahashi N et al (2008) Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 167(1):71–77

    Article  PubMed  Google Scholar 

  5. Song YJ et al (2008) Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17(3):712–716

    Article  PubMed  CAS  Google Scholar 

  6. Bettuzzi S et al (2006) Chemoprevention of human prostate cancer by oral administration of green tea atechins in volunteers with high-grade prostate intraepithelial neoplasia. Cancer Res 66(2):1234–1240

    Article  PubMed  CAS  Google Scholar 

  7. Shimizu M et al (2005) EGCG inhibits activation of Her3 and expression of Cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 5(1):69–78

    PubMed  Google Scholar 

  8. Inoue M (2001) Regular consumption of green tea and the risk of brast cancer recurrence: Follow up-study form the Hospital-based Epidemiologic Research Program at Aiichi Cancer Center. Cancer Lett 167:175–182

    Article  PubMed  CAS  Google Scholar 

  9. Seely D et al (2005) The Effect of Green tea consumption on Incidence of breast cenacer and recurrence of breast cancer, a systematic Review and Meta-analysis. Integr Cancer Ther 4(2):144–155

    Article  PubMed  Google Scholar 

  10. Zhang M et al (2004) Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer 112(3):465–469

    Article  PubMed  CAS  Google Scholar 

  11. Jatoi A et al (2003) A Phase II trial of green tea in the treatment of patients with androgen independent metastatic. Cancer 97(6):1442–1446

    Article  PubMed  CAS  Google Scholar 

  12. Ward H et al (2008) Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the european prospective into cancer-norfolk-study. Cancer Epidemiol Biomarkers Prev 17(10):2891–2894

    Article  PubMed  CAS  Google Scholar 

  13. Travis RC et al (2008) A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer 122(3):705–710

    Article  PubMed  CAS  Google Scholar 

  14. Seo HS et al (2006) Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat

  15. Garcea G et al (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br J Cancer 90:1011–1015

    Google Scholar 

  16. Garcea G et al (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients. Cancer Epidemiol Biomarkers Prev 14(1):120–125

    PubMed  CAS  Google Scholar 

  17. Dhillon N et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14(14):4491–4499

    Article  PubMed  CAS  Google Scholar 

  18. Epelbaum R et al (2008) Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 26 (May 20 suppl; abstr 15619)

  19. Sakano K et al (2002) Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch Biochem Biophys 405(2):223–230

    Article  PubMed  CAS  Google Scholar 

  20. Moy KA et al (2008) Urinary total isothiocyanates and colorectal cancer: a prospective study of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17(6):1354–1359

    Article  PubMed  CAS  Google Scholar 

  21. Tang L et al (2008) Consumption of raw cruciferous vegetables is inversly associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev 17(4):938–944

    Article  PubMed  CAS  Google Scholar 

  22. Peters U et al (2007) Serum lycopene other carotenoids and prostate cancer risk, a nested case-control study in the prostate, lung, colorectal and ovarian cancer screening trail. Cancer Epidemiol Biomarkers Prev 16(5):962–968

    Article  PubMed  CAS  Google Scholar 

  23. Boileau T et al (2003) Prostate carcinogenesis in N-methyl-N-nitrosourea (Nmu)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. JNCI J Natl Cancer Inst 95(21):1578–1586

    CAS  Google Scholar 

  24. Kavanaugh CJ et al (2007) The U.S. Food and Drug Administration’s evidence-based review for qualified health claims. J Natl Cancer Inst 99(14):1074–1085

    Article  PubMed  CAS  Google Scholar 

  25. Voskuil DW et al (2008) Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutr Cancer 60(3):342–353

    Article  PubMed  CAS  Google Scholar 

  26. Bowen P et al (2002) Tomato sauce supplementation and prostate cancer: Lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 227:886–893

    Google Scholar 

  27. Clark PE et al (2006) Phase I-II prospective dose-escalation trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 67(6):1257–1261

    Article  PubMed  Google Scholar 

  28. Jatoi A et al (2007) A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer, results of a Phase II study from the North Central Cancer Treatment Group. Urology 69(2):289–294

    Article  PubMed  Google Scholar 

  29. Schwenke C et al (2009) Lycopene for advanced hormone refractory prostate cancer: a prospective, open physe II pilot study. J Urol 181(3):1098–1103

    Article  PubMed  CAS  Google Scholar 

  30. Boulton DW et al (1998) Extensive binding of the bioflavonoid quercetin tho human plasma protein. J Pharm Pharmacol 50:243–249

    PubMed  CAS  Google Scholar 

  31. Lamson DW et al (2000) Antioxidants and Cancer III; Quercetin. Altern Med Rev 5(3):196

    PubMed  CAS  Google Scholar 

  32. Cui Y et al (2008) Dietary flavonoid intake and lung cancer–a population-based case-control study. Cancer 112(10):2241–2248

    Article  PubMed  CAS  Google Scholar 

  33. Ossola B et al (2008) Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology 250(1):1–8

    Article  PubMed  CAS  Google Scholar 

  34. Duthie SJ et al (1997) The effect of dietary flavonoids on DNA damage (strand breaks and oxidised pyrimidines) and growth in human cells. Mutat Res 390:141–141

    PubMed  CAS  Google Scholar 

  35. Liu FT et al (2008) Dietary flavonoids inhibit the anti-cancer effects of the proteasome inhibitor Bortezomib. Blood 112(9):3835–3846

    Article  PubMed  CAS  Google Scholar 

  36. Boocock DJ et al (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of Resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16(6):1246–1252

    Article  PubMed  CAS  Google Scholar 

  37. Chan JY et al (2008) Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther 7(8)

  38. Pearce VP et al (2008) Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene 27(17):2365–2374

    Article  PubMed  CAS  Google Scholar 

  39. Szende B et al (2000) Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32(2):88–92

    PubMed  CAS  Google Scholar 

  40. Ahmad KA et al (2003) Pro-oxidant activity of low doses of resveratrol inhibits hydrogen peroxide-induxed apoptosis. Ann N Y Acad Sci 1010:365–373

    Article  PubMed  CAS  Google Scholar 

  41. Wang TT et al (2008) Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis

  42. Laszczyk MN (2009) Pentacyclic triterpenes of the Lupane, Oleanane and Ursane Group as tools in cancer therapy. Planta Med (Epub ahead of print)

  43. Jäger S, Laszczyk MN, Strüh CM et al (2008) Triterpenes from natural sources for parenteral and topical application. Planta Med 74:1119

    Google Scholar 

  44. Huyke C, Reuter J, Rödig M et al (2009) Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 7:128–133

    PubMed  Google Scholar 

  45. Woelfle U, Laszczyk MN, Kraus M et al (2009) Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol 2009, Aug 13 (Epub ahead of print)

  46. Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, Jansen B et al. (2000) Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114:935–940

    Article  PubMed  CAS  Google Scholar 

  47. Saleem M, Maddodi N, Abu Zaid M et al (2008) Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res 14:2119–2127

    Article  PubMed  CAS  Google Scholar 

  48. Strüh C, Jäger S, Schempp CM et al (2008) Solubilized triterpenes from mistletoe show anti-tumor effects on skin-derived cell lines. Planta Med 74:1130

    Article  Google Scholar 

  49. Spahn G (2009) Eigene Anwendungsbeobachtung

  50. Fulda S, Jeremias I, Steiner HH et al (1999) Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82:435–441

    Article  PubMed  CAS  Google Scholar 

  51. Hostanska K, Daum G, Saller R (2002) Cytostatic and apoptosis-inducing activity of boswellic acids towards malignant cells in vitro. Anticancer Res 22:2853–2862

    PubMed  CAS  Google Scholar 

  52. Ammon HPT (2006) Boswellic acids in chronic inflammatory diseases. Planta Med 72:1100–1116

    Article  PubMed  CAS  Google Scholar 

  53. Flavin DF (2007) A lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol 82:91–93

    Article  PubMed  CAS  Google Scholar 

  54. Spahn G (2007) Ex oriente lux: Weihrauch, Myrrhe, Ingwer und Opium in der onkologischen Palliativ- und Supportivmedizin. Phytotherapie 1:12–17

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Bereich Palliativmedizin, supportive und komplementäre Onkologie, Universitäres Centrum für Tumorerkrankungen – UCT, Klinikum der J.W. Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60595, Frankfurt am Main, Deutschland

    J. Hübner

  2. Klinik Öschelbronn, Centrum für integrative Medizin und Tumottherapie, Niefern-Öschelbronn, Deutschland

    G. Spahn

  3. Universität Zürich, Zürich, Schweiz

    G. Spahn

Authors
  1. J. Hübner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Spahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Hübner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hübner, J., Spahn, G. Sekundäre Pflanzenstoffe. Onkologe 15, 1144–1150 (2009). https://doi.org/10.1007/s00761-009-1729-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-009-1729-6

Schlüsselwörter

Keywords

Search

Navigation